This trial is testing a new cancer drug to see what dose is safe and how well it works.
- Non-Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Small Lymphocytic Lymphoma
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myeloproliferative Neoplasms
5 Primary · 10 Secondary · Reporting Duration: Baseline through approximately 3.5 years
4 Treatment Groups
1 of 4
1 of 4
1 of 4
1 of 4
132 Total Participants · 4 Treatment Groups
Primary Treatment: PRT1419 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What are the venues in which this trial can be accessed?
"For the time being, 8 sites are running this clinical trial; Houston, Philadelphia and Orange City among them. To reduce commuting requirements if accepted into the study, applicants should prioritize selecting a nearby site." - Anonymous Online Contributor
How many participants are currently taking part in this clinical trial?
"Affirmative. Per the information found on clinicaltrials.gov, this medical trial opened to recruitment on March 22nd 2022 and was most recently updated in October 31st of that same year. 30 participants are required across 8 distinct sites." - Anonymous Online Contributor
Is this trial accepting new participants presently?
"According to information found on clinicaltrials.gov, this trial is actively enrolling patients at present. It was posted online for the first time on March 22nd 2022 and its details were recently updated in October of the same year." - Anonymous Online Contributor
Can a person expect any adverse effects from taking PRT1419?
"Considering the limited evidence of PRT1419's efficacy and safety, our team has assigned it a score of 1." - Anonymous Online Contributor